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Unpublished data extracted from our departmental
registry as part of an ongoing quality assurance program
indicated that, before 1995, postoperative strokes
occurred in conjunction with approximately 4% of the
CEAs that were performed with synthetic patches as com-
pared with only approximately 2% of those CEAs that
were performed with autogenous vein patches. Although
this difference might be clinically important, it could also
represent a selection bias related to patient comorbidities.
Because we have preferentially used vein patching during
CEA, we generally have restricted synthetic patching to
patients whose saphenous veins were no longer available
because they already had been used as bypass grafts in the
treatment of severe coronary artery or peripheral vascular
disease. To overcome this limitation in our outcome analy-
sis, we designed a prospective, randomized trial of saphe-
nous vein patching versus synthetic patching to help in the
decision of whether the choice of patch material signifi-
cantly influences the postoperative stroke rate of compara-
ble patients who undergo CEA.
PATIENTS AND METHODS
Experimental design, objectives, and hypothesis.
The study design was a prospective, randomized clinical
trial conducted at a single institution. The objective of the
study was to compare the early and late results of CEA
according to whether it was performed with either saphe-
Carotid endarterectomy (CEA) has been shown to
reduce the long-term stroke risk in patients who have
severe symptomatic or asymptomatic carotid stenosis.1-5
Nevertheless, the effectiveness of CEA may be compro-
mised if either the early result or the late outcome of the
operation is less than optimal.3,6 We, and others, have
found that saphenous vein patching is associated with
lower postoperative stroke and recurrence rates than is pri-
mary arteriotomy closure.7-9 The comparative effect of
Dacron graft patching on the overall outcome of CEA is
currently unknown because this issue has not been ade-
quately studied in a prospective manner.8,10,11
Consequently, the optimal patch material for CEA remains
controversial.11-13 Excellent outcomes have been reported
with the use of either autogenous or synthetic patch mate-
rials.7,9,14-18
From the aDepartment of Vascular Surgery and the bDepartment of
Biostatistics and Epidemiology, The Cleveland Clinic Foundation.
Competition of interest: nil.
Presented at the Fifty-fifth Annual Meeting of The Society for Vascular
Surgery, Baltimore, Md, Jun 10-11, 2001.
Reprint requests: Patrick J. O’Hara, MD, Department of Vascular Surgery,
Cleveland Clinic Foundation, 9500 Euclid Avenue, Cleveland, Ohio
44195 (e-mail: oharap@ccf.org).
Copyright © 2002 by The Society for Vascular Surgery and The American
Association for Vascular Surgery.
0741-5214/2002/$35.00 + 0 24/6/120047
doi:10.1067/mva.2002.120047
A prospective, randomized study of saphenous
vein patching versus synthetic patching during
carotid endarterectomy
Patrick J. O’Hara, MD,a Norman R. Hertzer, MD,a Edward J. Mascha, MS,b Leonard P. Krajewski,
MD,a Daniel G. Clair, MD,a and Kenneth Ouriel, MD,a Cleveland, Ohio
Objective: The objective of this study was the determination of whether the choice of either autogenous saphenous vein
(ASV) or synthetic material for patch angioplasty significantly influences the results after carotid endarterectomy
(CEA).
Methods: With Institutional Review Board approval, 195 patients (145 men and 50 women; mean age, 69 years) who
underwent 207 CEAs were prospectively randomized to arteriotomy closure with ASV or synthetic patches from July
1996 to January 2000. One hundred and one patients (52%) were randomized to the ASV cohort, and 94 (48%) were
randomized to the synthetic cohort. Aside from a slight gender imbalance (70% versus 79% male in the ASV versus the
synthetic group), there were no clinically important differences in baseline demographic variables, risk factors, or sur-
gical indications between the ASV and synthetic groups.
Results: With all 207 randomized procedures on an intent-to-treat basis, there were two early (<30 days) postoperative
deaths (1%). There were three perioperative strokes in the ASV cohort (3.0%) and two in the synthetic cohort (2.1%;
P = .99). Two of these early strokes occurred in a subset of nine patients who received neither patch material, all after
randomization but before CEA. Two patients in each group had late strokes. The cumulative freedom from stroke rate
at 1 year (ASV, 94%; synthetic, 95%) was virtually identical for both cohorts. With the 125 patients who had at least
one postoperative duplex scan, the incidence rate of recurrent (≥60%) carotid stenosis was 4.8% (three of 62) for the
ASV group and 6.3% (four of 63) for the synthetic group (P = .99).
Conclusion: No significant differences in the stroke, mortality, or restenosis rates were shown between the ASV and the
synthetic cohorts. While conceding the power limitations inherent in this study, we conclude that CEA may be safely
performed with similar early results with ASV or synthetic patches. (J Vasc Surg 2002;35:324-32.)
nous vein patches or knitted Dacron graft patches. The
primary endpoint of the study was stroke at any time dur-
ing the follow-up period. Secondary endpoints included
stroke within 30 days of the surgical procedure, recurrent
carotid stenosis on follow-up duplex scanning, death dur-
ing the follow-up period, death within 30 postoperative
days, and local complications, such as hematoma, infec-
tion, or pseudoaneurysm. The hypothesis was that saphe-
nous vein patching would yield results that were
significantly superior to those of Dacron graft patching.
Sample size determination. Data from our depart-
mental registry with 2109 patients who underwent CEA
from January 1989 through October 1995 were used to
calculate the appropriate sample size for each of the two
randomized cohorts in this study. These retrospective data
revealed in-hospital perioperative stroke rates of approxi-
mately 4% for Dacron graft patching and 2% for vein patch-
ing. (Our registry contains no follow-up data regarding
recurrent stenosis.) On the basis of this information, a total
of 1320 patients (660 patients in each cohort) was deter-
mined to be necessary for an adequate randomized trial
that would compare the two techniques for patch angio-
plasty. The following assumptions were made for these cal-
culations: 1, the 5-year postoperative stroke rate for the
saphenous vein group was expected to be between 2% and
4% and was expected to be better than in the Dacron graft
group; 2, we wanted to be able to detect differences of 2%
or more in the 5-year stroke rate with 90% power at the .05
significance level with the comparison of the survival dis-
tributions with the log-rank test; 3, the dropout rate for
the patients enrolled in the trial was assumed to be less than
10%; and 4, with the assumption of an acquisition rate of
264 CEAs per year on the basis of historical data, it was
projected to take approximately 5 years to enroll an ade-
quate number of patients for analysis.
Patient selection and randomization. The trial was
monitored with a formal group sequential stopping rule
that was based on the sequential conditional probability
ratio test with five interim data analyses.19 The interim
analysis schedule was determined by the information time,
which is a function of the number of events, rather than
the calendar time. The trial was designed to be terminated
early if a significant difference in primary endpoint rates
became evident between the two randomized cohorts or if
it could be determined that the trial would not be able to
detect a 50% reduction in the event rates on the basis of
the discordant probability.19,20 Sample sizes were free to
be adjusted on the basis of the emerging evidence with
sequential methods.20,21 Eligible patients were prospec-
tively randomized to either autogenous saphenous vein
(ASV) patching or to synthetic patching (with knitted
Dacron graft) before operation according to a computer-
generated randomization scheme. The synthetic patches
were knitted Dacron grafts, although the particular brand
was not assigned. During the study interval, the operating
room stocked both the regular Hemashield as well as the
Finesse Hemashield patches (Boston Scientific Corp,
Natick, Mass). Patch assignment was done with sealed,
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sequenced envelopes. Randomized patients who also
underwent a subsequent contralateral CEA were reas-
signed the same patch material for the contralateral proce-
dure. Patients were excluded from this study, and
therefore from randomization, only if they declined to
participate after receiving full disclosure, if an adequate
segment of the saphenous vein was known to be unavail-
able in either groin before CEA, if the proposed CEA rep-
resented a carotid reoperation or was scheduled to be
combined with a cardiac procedure, or if there was any
evidence of local or systemic sepsis.
Clinical follow-up examination and data collec-
tion. Baseline demographic data, such as age, gender, and
associated cardiovascular risk factors, were recorded for all
randomized patients at the time of their operations. The
same data were also obtained prospectively for all other
nonrandomized patients who underwent CEA during the
same study period. Our routine follow-up examination
protocol after any CEA consisted of an outpatient evalua-
tion at the 4th to 6th postoperative week and annually
thereafter. Each annual follow-up visit included a carotid
duplex scan as well as a standard history and physical
examination. All the patients were counseled to report any
interval neurologic or monocular visual symptoms, and
most patients underwent daily aspirin therapy unless there
was a specific contraindication to its use.
The duplex scan criteria for 80% to 99% stenosis of
the internal carotid artery (ICA) required both a peak sys-
tolic velocity of more than 240 cm/s and an end-diastolic
velocity of 135 cm/s or more. For 60% to 79% ICA
stenosis, a peak systolic velocity of more than 150 cm/s
but less than 240 cm/s with spectral broadening was nec-
essary. For 40% to 59% ICA stenosis, a peak systolic veloc-
ity of more than 105 cm/s but less than 150 cm/s with
spectral broadening was required. For 20% to 39% ICA
stenosis, a peak systolic velocity of less than 105 cm/s
with spectral broadening was necessary. And for 0 to 19%
ICA stenosis, a peak systolic velocity of less than 105
cm/s with no spectral broadening was required.22 These
criteria have been verified by our own correlations with
angiography in the past.
The data were collected as they were generated and
then were entered into an Oracle Database system (Oracle
Corporation, Redmond Shores, Calif) for periodic analysis.
Late follow-up data were collected for randomized
patients, but the follow-up data were not archived for the
nonrandomized patients after their discharge from the hos-
pital. This investigation was approved by the Institutional
Review Board of the Cleveland Clinic Foundation and was
funded with a grant from the Research Programs
Committee. No outside funding was provided.
Randomization began on July 1, 1996, but it eventu-
ally became evident that patient enrollment was failing to
meet our initial expectations. After 3 years of randomiza-
tion, the approximate recruitment rate was just 60 patients
annually. Furthermore, the interim data analyses had failed
to show any differences in the clinical endpoints between
the randomized cohorts. Once we had calculated that it
would require more than 20 years to satisfy the recruitment
target that had been established in our original attempt to
exclude the possibility of a type II statistical error, the
enrollment phase of the study was terminated (December
31, 1999) after only 195 patients had been randomized.
Statistical analysis. Randomized groups were
descriptively compared on baseline characteristics and
were compared on early (30-day) postoperative outcomes
with likelihood ratio, χ2, or Fisher exact tests. Kaplan-
Meier method estimates of survival and their 95% confi-
dence intervals (CIs) were calculated for overall survival
and freedom from stroke rates and then were compared
with the log-rank test results. Conditional power analyses
were conducted during interim analyses as planned.23
Intent-to-treat and actual group analyses were performed
for all outcomes of interest. A significance level of .05 was
designated for each hypothesis. Statistical software from
SAS Inc (Cary, NC) was used for all analyses.
RESULTS
The 195 patients in the randomized cohorts under-
went 207 CEAs, 12 of which were bilateral. The baseline
descriptive factors for the randomized patients are sum-
marized in Table I.
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During the same study period, 776 additional CEAs
were performed in 741 nonrandomized patients. Thus, the
randomized operations represented 21% of the 983 CEAs
that were performed by the members of our department
from July 1996 through December 1999. An algorithm that
illustrates the management of all 936 patients who under-
went surgical treatment during this period of study is pre-
sented in Fig 1. One hundred and one (52%) of the 195
randomized patients were assigned to ASV patching, and 94
(48%) were assigned to synthetic patching. Aside from a
slight gender imbalance (70% versus 79% male in the ASV
versus the synthetic group), there were no clinically impor-
tant differences between the baseline demographic variables,
risk factors, or surgical indications for the ASV and synthetic
cohorts on an intent-to-treat basis (Table I). Ninety-five
(49%) of the randomized patients actually underwent ASV
patching; 91 (47%) underwent synthetic patching, and nine
(4%) had neither patch material. There were no significant
differences in baseline demographic variables, risk factors, or
surgical indications for the ASV or the synthetic groups on
the basis of the actual treatment that was provided, with the
single exception that men comprised 68% of the ASV cohort
in comparison with 81% of the synthetic cohort 
(P = .042).
Table I. Comparison of randomized groups with respect to baseline descriptive factors, patch material, and variables
for 195 patients and 207 operations
Vein patch Synthetic patch
Descriptive factor Variable Total n % n %
Gender Male 145 71 70 74 79
Risk factor
Smoking 62 39 39 23 25
DM 58 33 33 25 27
HTN 140 74 73 66 70
CAD 113 56 56 57 61
COPD 27 15 15 12 13
Creatinine level, ≥2.0 mg/dL 12 5 5 7 7
Symptoms
Asymptomatic 121 50 59 61 65
Amaurosis 20 12 12 8 9
TIA 29 18 18 11 12
Stroke 21 9 9 12 13
VBI 5 3 3 2 2
Urgency
Elective 160 86 88 74 83
Nonelective 27 12 12 15 17
Preoperative stenosis
Ultrasound scan
Ipsilateral, ≥80% 155 77 78 78 84
Contralateral, ≥80% 37 22 22 15 16
Angiography
Ipsilateral, ≥80% 108 49 75 59 91
Contralateral, ≥80% 31 16 25 15 23
Total Vein Synthetic
n Mean (SD) n Mean (SD) n Mean (SD)
Age (y) 195 69 (9.1) 94 69 (9.4) 101 69 (8.9)
DM, Diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack;
VBI, vertebrobasilar insufficiency; SD, standard deviation.
Follow-up examination was complete for 191 patients
(203 operations) in the randomized cohorts. The remain-
ing four patients either were lost after hospital discharge or
did not undergo CEA after randomization. The median
follow-up period was 15 months (mean, 18 months; max-
imum, 51 months). One hundred and twenty-five of the
203 CEAs (62%) were evaluated with at least one postop-
erative duplex scan at a median interval of 18 months
(maximum, 51 months).
Early mortality and morbidity rates. The 30-day
mortality and morbidity rates for the randomized cohorts
are summarized on an intent-to-treat basis in Table II.
With all 195 patients, there were two early deaths (1.0%):
one from a myocardial infarction 26 days after planned
CEA with ASV patching and the other from multisystem
organ failure after initial randomization to synthetic patch-
ing. There were five early strokes (2.4%) after the 207
CEAs. These included three perioperative strokes in the
ASV cohort (2.8%; 95% CI, 0.6% to 8.4%) and two in the
synthetic cohort (2.0%; 95% CI, 0.3% to 7.5%; P = .99).
The 95% CI for the difference between the groups (ASV
minus synthetic) is –6.3% to 11.8%. The early stroke rate
was 2.1% (n = 2) for the 95 patients who actually under-
went vein patching, 1.1% (n = 1) for the 91 patients who
actually underwent synthetic patching (P = .99), and 22%
(n = 2) for the nine patients who did not undergo CEA or
patching at all.
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Nine randomized patients are not considered to have
undergone either ASV or synthetic patching. One of these
patients was randomized to ASV but instead underwent
eversion endarterectomy without a postoperative stroke.
Two patients, one of whom was randomized to ASV
patching and the other to synthetic patching, underwent
CEA at another hospital. Neither of these patients had a
stroke, but no information is available concerning the
methods that were used to repair their arteriotomies.
Another patient was randomized to synthetic patching but
subsequently underwent simultaneous aortic valve
replacement, myocardial revascularization, and CEA else-
where. No details regarding the arteriotomy closure are
available for this patient who died with multisystem failure
22 days after the combined procedure without having sus-
tained a stroke. The remaining five patients, four of whom
had been randomized to synthetic patching and one to
ASV patching, did not undergo CEA. Three of these
patients (two randomized to synthetic patching and one
to ASV patching) eventually did have strokes.
Nineteen postoperative complications (8.7%) were
recorded in our database for the 207 randomized CEAs
and included cardiac (arrhythmia, myocardial infarction,
and congestive heart failure) and neurologic (stroke and
cranial nerve injury) events, pneumonia, and an exacerba-
tion of peptic ulcer disease. One patient had a cervical
hematoma that required a reoperation after vein patching,
Fig 1. Algorithm illustrates surgical management for all 936 patients who underwent 983 carotid
endarterectomies from July 1996 through July 2000.
Table II. Comparison of randomized groups with respect to early mortality and morbidity rates on intent-to-treat
basis for 195 patients and 207 operations
Vein (n = 106) Synthetic (n = 101)
Factor Total n % n % P value*
Mortality rate (30 days) 2 1 0.9 1 1.0 .99
Stroke (30 days) 5 3 2.8 2 2.0 .99
Reoperation 3 1 0.9 2 2.0 .61
Any hospital complication 19 10 9.4 9 8.9 .99
*P value determined with Fisher exact test.
but no cervical or groin infections occurred. On an intent-
to-treat basis, there were no significant differences
between the postoperative complication or reoperation
rates in the ASV and synthetic cohorts (Table II).
Late survival and freedom from stroke. Eight late
deaths have occurred in the randomized cohorts (ASV,
four of 101; synthetic, four of 94). The probable cause of
late death was cardiac-related in two patients (25%), renal
failure in two patients (25%), stroke (12%) or cancer (12%)
each in one patient, and unknown causes in two patients.
Kaplan-Meier method survival estimates for all 195 ran-
domized patients are illustrated in Fig 2. The cumulative
survival rates at 1 year are virtually identical for the
assigned treatment groups (ASV, 97% [95% CI, 94% to
100%]; synthetic, 96% [95% CI, 92% to 100%]; P = .53).
Two additional patients in each randomized cohort
have had late strokes. Kaplan-Meier method estimates
regarding the overall freedom from stroke rates are illus-
trated for all 195 randomized patients in Fig 3. The esti-
mated cumulative freedom from stroke rate at 1 year is
nearly identical for the randomized cohorts, irrespective of
whether it is calculated on an intent-to-treat basis (ASV,
94% [95% CI, 89% to 99%]; synthetic, 95% [95% CI, 90%
to 100%]; P = .75) or according to the patch material that
actually was used (ASV, 95% [95% CI, 90% to 100%]; syn-
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thetic, 97% [95% CI, 94% to 100%]; P = .40). The stan-
dard error is 5 or less for each of the randomized groups
in each of the life tables at 48 months.
Recurrent stenosis. With the 125 randomized
patients who actually received patches and who also had
each had at least one postoperative duplex scan, the
median follow-up interval to the time of the most recent
scan was 17 months (maximum, 51 months) for the ASV
cohort and 22 months (maximum, 47 months) for the
synthetic cohort. The results are summarized in Table III.
Recurrent ≥60% stenosis has been documented only in
three of the 62 patients for ASV patching (4.8%) and in
four of the 63 patients for synthetic patching (6.3%; P =
.99), and none had strokes.
Comparison with nonrandomized patients. The
descriptive features of the 195 randomized patients are
compared with those of the 741 nonrandomized patients
(776 operations) in Table IV. Aside from a gender imbal-
ance (74% versus 66% male in the randomized cohorts ver-
sus the nonrandomized group [P = .02]) and a difference
in use of the two patch materials (49% versus 29% syn-
thetic in the randomized cohorts versus the nonrandom-
ized group [P = .01]), there were no statistically
significant distinctions in baseline variables, risk factors, or
surgical indications between the randomized and the non-
Fig 2. Kaplan-Meier method survival rate estimates for 195 randomized patients. Vertical bars represent
95% confidence intervals. (Calculations on basis of intent-to-treat analysis.) Standard error is 5 or less for
each randomized group at 48 months.
Table III. Restenosis detected with postoperative duplex scans for 125 randomized patients
Degree of stenosis
Patch material 0% to 19% 20% to 39% 40% to 59% 60% to 79% 80% to 99% Occlusion Total
Synthetic 48 (77%) 7 (11%) 4 (6%) 1 (2%) 0 ( 2 (3%) 62
Vein 47 (75%) 9 (14%) 3 (5%) 1 (2%) 2 (3%) 1 (2%) 63
Total 95 (76%) 16 (13%) 7 (6%) 3 (2%) 2 (1%) 3 (2%) 125
randomized patients. Likewise, there were no significant
differences between the randomized and the nonrandom-
ized patients with respect to the 30-day stroke, mortality,
reoperation, or in-hospital complication rates (Table V).
Conditional power analysis. This study was origi-
nally designed for a power of 0.90 to detect a difference
of 2% or more in the 5-year event rate. A conditional
power analysis was performed after 195 patients had
been enrolled for the estimation of the probability of
obtaining a statistically significant result if the study
were to continue until the entire planned enrollment
was acquired.23 In this analysis, the following three pos-
sible scenarios that the treatment effect might take for
the rest of the study were considered: no treatment dif-
ference (the null hypothesis), a 2% difference (the alter-
native hypothesis), or the observed treatment effect
(current trend). If the current trend (approximately a 1%
difference between the treatment groups) were to have
continued, there would have been only a 17% chance
that the study would find a significant difference in the
stroke outcome and a 42% chance that the study would
find a significant difference in the mortality outcome
with our intent-to-treat results (Table VI). With the
sample size of 195 patients that we actually enrolled and
the nine strokes that we actually observed before the
trial was stopped for practical reasons (in contrast to the
55 strokes that were expected from the study design),
the analysis we performed had 90% power to detect a
12% or more difference in the event rate between the
treatment groups.
DISCUSSION
The choice of patch material that will provide opti-
mum results during CEA remains controversial.12,24-27 In
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a collective review of several randomized trials of carotid
patching, Counsell, Salinas, and Warlow28 and Counsell et
al29 concluded that there is not yet enough evidence in the
literature to permit any definitive conclusions concerning
the superiority of either ASV or synthetic patching. The
purpose of our own prospective randomized trial was to
determine whether the choice of patch material signifi-
cantly influences the results after CEA at a high-volume
center for vascular surgery. Although we initiated our
study under the assumption that saphenous vein patching
was intrinsically superior to synthetic patching, we did not
show significant differences in early and intermediate post-
operative stroke, mortality, or morbidity rates in a total of
195 randomized patients. We also did not show a signifi-
cant advantage for either patch material in the prevention
of recurrent ≥60% stenosis on the basis of postoperative
duplex scanning that was performed at a median follow-up
interval of 19 months.
There have been many previous attempts to identify
the most appropriate material for carotid patching.
Goldman et al13 found no significant differences in post-
operative mortality, morbidity, or restenosis rates in a ret-
rospective study of 275 consecutive CEAs with saphenous
vein, jugular vein, and Dacron patches. Lord et al15 were
unable to show a difference in total postoperative neuro-
logic complications between vein and polytetrafluoroeth-
ylene (PTFE) patches in a randomized series of 140 CEAs,
although patching appeared to yield results that were
superior to primary closure. In a study that was similar 
to our own, Katz and Kohl25 randomized 190 patients 
to receive 207 patch closures with either Dacron graft 
or saphenous vein graft from the thigh but also did 
not show significant differences between the two groups
with respect to perioperative stroke or infection rates.
Fig 3. Kaplan-Meier method estimates for freedom from stroke in 195 randomized patients. Vertical bars
represent 95% confidence intervals. (Calculations on basis of intent-to-treat analysis.) Standard error is 5
or less for each randomized group at 48 months.
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Gonzalez-Fajardo, Perez, and Mateo26 conducted a study
of 84 patients (95 CEAs) who were randomized to vein
patching or to PTFE patching and found no significant
difference between the incidence of carotid thrombosis,
restenosis, or neurologic complications in the two groups.
In a study of 399 CEAs that were randomized to primary
closure, vein patches, or PTFE patches, AbuRahma et al30
also reported a comparable lower postoperative stroke rate
with either type of patch material as compared with pri-
mary closure and discovered that PTFE patches appeared
to have an advantage over vein patches in the reduction of
the risk for subsequent neurologic complications and
restenosis.
The major limitation of these comparatively small
series, as well as our own, is statistical power.24 This study
was originally designed to show a 2% difference between
ASV and synthetic groups with a power of 0.9, thus
requiring 1320 patients (660 patients in each group) to
avoid a false-negative conclusion. Our patient volume sug-
gested that this study could be feasible if recruitment were
Table IV. Comparison of randomized with nonrandomized cohorts with respect to baseline descriptive factors and
variables
Randomized Nonrandomized 
Descriptive factor Variable (n = 195 patients) (n = 741 patients) P value*
Treatment received <.001†
Other/none 9 (5%) 42 (6%)
Synthetic 95 (49%) 202 (27%)
Vein 91 (47%) 497 (67%) .02
Gender Male 145 (74%) 487 (66%) .02
Risk factors
Smoking 62 (32%) 210 (28%) .34
DM 58 (30%) 217 (29%) .89
HTN 140 (72%) 571 (77%) .14
CAD 112 (57%) 479 (65%) .07
COPD 27 (14%) 102 (14%) .97
Creatinine level, ≥2 mg/dL 12 (6%) 739 (5%) .16†
Symptoms
Asymptomatic 74 (38%) 254 (34%) .34
Amaurosis 20 (10%) 60 (8%) .34
TIA 29 (15%) 104 (14%) .76
Stroke 21 (11%) 77 (10%) .87
VBI 5 (3%) 20 (3%) .92
Urgency
Elective 161 (86%) 617 (83%) .095
Nonelective 25 (14%) 125 (17%)
Preoperative/stenosis (n = 207 operations) (n = 776 operations)
Ultrasound scan
Ipsilateral, ≥80% 155 (81%) 614 (83%) .54
Contralateral, ≥80% 37 (19%) 175 (24%) .2
Angiography
Ipsilateral, ≥80% 108 (83%) 458 (81%) .57
Contralateral, ≥80% 31 (24%) 161 (29%) .28
*P value determined with χ2 or Fisher exact test.
†P value determined with Fisher exact test.
DM, Diabetes mellitus; HTN, hypertension; CAD, coronary artery disease; COPD, chronic obstructive pulmonary disease; TIA, transient ischemic attack;
VBI, vertebrobasilar insufficiency.
Table V. Comparison of randomized with nonrandomized cohorts with respect to early postoperative mortality and
morbidity rates (30 days for randomized patients and for hospitalization period for nonrandomized patients)
Randomized Nonrandomized
(n = 195 patients and 207 operations) (n = 741 patients and 776 operations)
Factor Total n % n % P value*
Mortality rate 9 2 (1.0%) 7 (0.9%) .99†
Stroke 19 5 (2.4%) 14 (1.8%) .57†
Reoperation 19 3 (1.5%) 16 (2.1%) .79†
Any hospital complication 99 19 (9.2%) 80 (10.3%) .23 
*P value determined with χ2 or Fisher exact test.
†P value determined with Fisher exact test.
robust and especially if interval analysis were to show the
emergence of a significant difference between the study
groups. Our recruitment rate probably was influenced by
investigator bias in favor of vein patching that may have
limited the number of women who were enrolled in the
trial and by the concerns that were raised among many
patients with the lengthy consent document that was
thought to be prudent by our Institutional Review Board
even though two standard forms of therapy were being
administered. Although the 21% recruitment rate that we
achieved compares favorably with the 5% screening rate for
the symptomatic CEA trial that was conducted by the
Veterans Affairs Cooperative Studies Program,31 it was
insufficient to allow the completion of our enrollment
goal within a reasonable period of time. Although our
investigation is underpowered to prove conclusively that
the early results of these two patch materials are equiva-
lent, we can conclude with 95% confidence that the dif-
ference between them, if one exists at all, would be less
than 12%.
Patching itself, rather than the choice of a specific
patch material, may prove to be the most important ele-
ment to consider in the improvement of the safety and
durability of CEA.32 Those surgeons who prefer the qual-
ities of saphenous vein should continue to use it, but, if
vein is unavailable or would better be used for another sur-
gical purpose, synthetic patching clearly does not appear to
place patients at any measurable risk for unfavorable results
during the perioperative or intermediate follow-up period.
Our results seem to encourage flexibility in choosing the
patch material for carotid closure. Further studies will be
necessary to determine whether the qualities of saphenous
vein will prove to be advantageous in the long term.
If no clinically important difference in morbidity or
mortality rates associated with the use of the two patch
materials can be reliably shown, it seems likely that syn-
thetic material would be favored simply because it would
spare autologous vein for other uses and it would obviate
the need for an additional leg incision. Because the late
stroke and restenosis rate after CEA is impressively low
(2% to 3%) with any type of patch,1,2,4,5,10,33 a large num-
ber of patients would be necessary to prove the superior-
ity of one patch material over another and even larger
numbers of patients would be required to show their
equivalence. Until the results of a prospective randomized
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trial of this magnitude are available, we can only conclude
with the power limitations in our study that CEA may be
safely performed with either ASV or synthetic patches with
similar early results in our own setting.
We thank Becky Roberts who maintains our depart-
mental database and Edwin G. Beven, MD, who provided
patients for this series before his retirement in 1999.
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Dr Ali F. AbuRahma (Charleston, WVa). I commend you for
this well-designed study. Unfortunately, like most of us who strug-
gle when we go with the carotid patching, do we have enough of
a number? And from a guy who has done three of them in the last
10 years, I could really feel sympathy with you. But that doesn’t
prevent me from asking you a couple of questions.
What synthetic patches did you use? And if you did use a
Dacron, and I presume the majority were Dacron, was the Dacron
the conventional Hemashield patch or was it the Finesse patch? I
think that’s critical for the audience to realize there is a big differ-
ence, at least in our observation, between the Finesse patch and
the conventional Hemashield patch. And secondly, how do you try
to find the difference between the conclusion you made to us and
the beautiful work by Joe Archie in his meta-analysis when there
was a definite trend towards vein as superior to synthetics. And we
even looked to synthetics; Dacron was somewhat inferior to PTFE
when it came to preoperative stroke and restenosis. And as you
know, that work, I’m sure most of you are aware of, was meta-
analysis of big time, prospective, randomized trial.
Dr Patrick J. O’Hara. The first question regarding patch
material is easier to answer. This study was done over more than
a 3-year period with several different surgeons involved. All the
synthetic patches were Dacron, and I believe most of them were
the Finesse patches, but some of them could have been the regu-
lar Hemashield Dacron patches. We didn’t specify the particular
Dacron patch material to use for the study, and we carry both
Dacron patches in stock.
As for the second question, how we reconcile our findings
with Dr Archie’s meta-analysis, the short version of the answer is
I don’t know. These results are what we found, and clearly there
are power limitations to this study. However, from a practical
point of view, given almost 900 patients, 200 of which were
prospectively randomized, we still couldn’t demonstrate a differ-
ence in results between patch materials. We believe that a differ-
ence, if it exists, is probably not huge. I think that’s the most we
can conclude from our results.
Dr Geun Eun B. Kim (Seoul, South Korea). I did a similar
study of bovine patch versus vein, and results are good in both.
But operating time is about 20 minutes less in the bovine group.
Did you find the same with the synthetic?
Second, I do a routine MRA and duplex study before and
after the operation. Did you just do preoperative carotid duplex
study? With preoperative and postoperative studies, one could
evaluate the technical details.
Dr O’Hara. Regarding the time question, those data probably
are available, but we didn’t specifically measure them prospec-
tively as part of the study. Consequently, I don’t know whether
there were significant time differences between using the vein or
the synthetic patch. I suspect there probably were some time sav-
ings because there is one less incision with the synthetic, but I
don’t have those data.
As far as the use of duplex, most of these patients were done
on the basis of duplex alone. Some patients were referred to us
with arteriograms already performed, but our general tendency is
to do the operation based on duplex alone unless there is some
unusual issue to resolve.
Dr James M. Malone (Scottsdale, Ariz). Those of us that are
not routinely patchers still bow at the altar of gender difference.
What can you tell us about gender differences?
Dr O’Hara. In this study we did not detect any difference in
outcome between the men and the women, so I really can’t
resolve the issue of gender differences in outcome.
Dr Thomas F. O’Donnell, Jr (Boston, Mass). You had very
few restenoses, but where did they occur anatomically in the
carotid endarterectomy site? Was there any consistency or were
they just random?
Dr O’Hara. I think there were so few restenoses that I would
have to relook at the data to see if there was any consistent pat-
tern. Since there were very few restenoses, I can’t recall a partic-
ular pattern.
DISCUSSION
